Moody's assigns B2 CFR to PharMerica Corporation; outlook stable
Rating Action: Moody's assigns B2 CFR to PharMerica Corporation; outlook stable. Global Credit Research- 12 Sep 2017. New York, September 12, 2017-- Moody's Investors Service today assigned a B2 Corporate Family Rating and B2-PD Probability of Default Rating to PharMerica Corporation.Pharmedic Pharmaceutical Medicinal JSC. Pharmedic Pharmaceutical Medicinal Joint Stock Company is a Vietnam-based company principally engaged in the manufacturing and distributing of pharmaceutical products, medicines, cosmetic and other products used in the healthcare sector. In addition, the Company is involved in the provision of printing services of plastic, paper and aluminum packagings. Moreover, it is active in the manufacture and trading of chemical products, such as pesticides and detergents for household and medical usage. During the year ended December 31, 2012, 97.24% of the Company's total revenue came from the sale of finished products. As of December 31, 2012, the Company was an affiliate of Saigon Pharmaceutical Company Limited (SAPHARCO), and it had a factory in Ho Chi Minh City, Vietnam.
Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:
- 130 countries
11,000 corporate issuers
21,000 public finance issuers
76,000 structured finance obligations
Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.
Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.